Lack of function of an N-ethylmaleimide-sensitive thiol protein in erythrocyte membrane of autosomal dominant polycystic kidney disease.
The polycystic kidney disease 1 (PKD1) gene product polycystin has been predicted to be an integral membrane protein involved in cell-cell and cell-matrix interactions. The erythrocyte membrane fluidity in autosomal dominant polycystic kidney disease (ADPKD) patients is increased, and this may be due to a membrane cytoskeletal abnormality. The abnormal erythrocyte sodium-lithium countertransport kinetics in-ADPKD are related to an altered thiol protein in the cytoskeleton. The possibility that a similar thiol protein abnormality causes the increased erythrocyte membrane fluidity in ADPKD was investigated. The membrane fluidity of intact erythrocytes from 12 ADPKD patients and 12 healthy control subjects was assessed from the fluorescence anisotropies of 1,6-diphenyl-1,3,5-hexatriene (DPH) and trimethylammonium-diphenyl-hexatriene (TMA-DPH). The effect on membrane fluidity of N-ethylmaleimide (NEM), cytochalasin D, heating at 48 degrees C for 20 min, or more specifically, liposomes containing antibodies to actin or ankyrin, was determined. In erythrocytes from healthy control subjects, the fluorescence anisotropy of DPH (mean +/- SEM: 0.223 +/- 0.001) was decreased after treatment with NEM (0.200 +/- 0.003, P < 0.001), cytochalasin D (0.206 +/- 0.006, P < 0.001), heating (0.199 +/- 0.002, P < 0.001), and antibodies to actin (0.194 +/- 0.002, P < 0.001) or ankyrin (0.196 +/- 0.002, P < 0.001). The TMA-DPH anisotropy (0.279 +/- 0.001) was also decreased after treatment with NEM (0.264 +/- 0.001, P < 0.001), cytochalasin D (0.264 +/- 0.001, P < 0.001), heating (0.265 +/- 0.001, P < 0.001), and antibodies to actin (0.262 +/- 0.002, P < 0.001) or ankyrin (0.262 +/- 0.002, P < 0.001). NEM had no additional effect on the other treatments, suggesting that its target thiol protein was associated with the cytoskeleton. In untreated erythrocytes from ADPKD patients, fluorescence anisotropies of both DPH and TMA-DPH were reduced, and none of the treatments altered the anisotropy of either DPH or TMA-DPH. In ADPKD, a cytoskeletal thiol protein is abnormal and possibly explains abnormal lipid bilayer properties and transport protein function in erythrocytes in this disease.
Vareesangthip
K
K
Department of Medicine (Nephrology), Medical School, University of Newcastle-upon-Tyne, United Kingdom.
Wilkinson
R
R
Thomas
T H
TH
D000199:Actins / Q000276:immunology; D000328:Adult; D000418:Albumins / Q000276:immunology; D017487:Ankyrins / Q000276:immunology; D000906:Antibodies / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology; D003599:Cytoskeleton / Q000502:physiology; D004161:Diphenylhexatriene / Q000031:analogs & derivatives; D004337:Drug Carriers; D004910:Erythrocyte Membrane / Q000378:metabolism*; D005033:Ethylmaleimide / Q000494:pharmacology*; D005260:Female; D005456:Fluorescent Dyes; D006801:Humans; D008081:Liposomes; D008297:Male; D008560:Membrane Fluidity / Q000187:drug effects; D008875:Middle Aged; D016891:Polycystic Kidney, Autosomal Dominant / Q000097:blood*; D012016:Reference Values; D013438:Sulfhydryl Compounds / Q000502:physiology*
D000199:Actins; D000418:Albumins; D017487:Ankyrins; D000906:Antibodies; D004337:Drug Carriers; D005456:Fluorescent Dyes; D008081:Liposomes; D013438:Sulfhydryl Compounds; D004161:Diphenylhexatriene; C033628:1-(4-(trimethylamino)phenyl)-6-phenylhexa-1,3,5-triene; D005033:Ethylmaleimide